Skip to main content

MicroRNA Patents in Demyelinating Diseases: A New Diagnostic and Therapeutic Perspective

Buy Article:

$105.00 plus tax (Refund Policy)

MicroRNAs (miRNAs, miRs) are a class of non-coding single-stranded RNAs, which can negatively regulate gene expression at posttranscriptional levels by miRNA-mRNA interaction. It has been demonstrated that miRNAs play important roles in a variety of biological process, including cell proliferation, differentiation, apoptosis, and tumorigenesis. Recent studies have shown crucial roles of specific miRNAs in controlling oligodendrocyte (OL) differentiation and myelination. Dysregulation of miRNAs is a vital event in the pathogenesis of demyelinating diseases. Furthermore, new patents of miRNAs also provide new strategies for gene therapy and miR-drug development for demyelinating diseases, especially multiple sclerosis. In this review, we briefly introduce the roles of miRNAs in OL differentiation and in the pathogenesis of demyelinating diseases, with emphasis on the implication of miRNAs patents in disease diagnostic and therapeutic perspective and its related technologies and challenges in clinical application.

No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: Central nervous system; DEMYELINATION-RELATED DISEASES; DISEASE BIOMARKERS; EAE; MULTIPLE SCLEROSIS; MiRNAs; NOVEL MiRNAs; Oligodendrocyte progenitor cells; antagomirs; demyelinating diseases; miR-drug; microRNAs; multiple sclerosis; oligodendrocyte; patents

Document Type: Research Article

Publication date: 2012-04-01

More about this publication?
  • Recent Patents on DNA and Gene Sequences publishes review articles by experts on recent patents on DNA and gene sequences. A selection of important and recent patents in the field is also included in the journal. The journal is essential reading for all researchers involved in applied molecular biology.
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more